Literature DB >> 17093289

Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.

Sotirios Tsimikas1, Emmanouil S Brilakis, Ryan J Lennon, Elizabeth R Miller, Joseph L Witztum, Joseph P McConnell, Kenneth S Kornman, Peter B Berger.   

Abstract

The relationship between autoantibodies to oxidized low density lipoprotein (OxLDL) and coronary artery disease (CAD) remains controversial. IgM and IgG OxLDL autoantibodies to malondialdehyde (MDA)-modified LDL, copper oxidized low density lipoprotein (CuOxLDL), and oxidized cholesterol linoleate (OxCL), as well as apolipoprotein B-100 immune complexes (apoB-ICs), were measured in 504 patients undergoing clinically indicated coronary angiography. Patients were followed for cardiovascular events for a median of 4 years. In univariate analysis, IgM OxLDL autoantibodies and IgM apoB-ICs were inversely associated with the presence of angiographically determined CAD, whereas IgG OxLDL autoantibodies and IgG apoB-ICs were positively associated. In logistic regression analysis, compared with the first quartile, patients in the fourth quartile of IgM OxLDL autoantibodies and apoB-ICs showed a lower probability of angiographically determined CAD (>50% diameter stenosis). Odds ratios and (95% confidence intervals) were as follows: MDA-LDL, 0.51 (0.32-0.82; P = 0.005); CuOxLDL, 0.63 (0.39-1.01; P = 0.05); OxCL, 0.63 (0.39-1.01; P = 0.05); and apoB-IC, 0.55 (0.34-0.88; P = 0.013). These relationships were accentuated in the setting of hypercholesterolemia, with the highest IgM levels showing the lowest risk of CAD for the same level of hypercholesterolemia. Multivariable analysis revealed that neither IgM or IgG OxLDL autoantibodies nor apoB-ICs were independently associated with angiographically determined CAD or cardiovascular events. In conclusion, IgG and IgM OxLDL biomarkers have divergent associations with CAD in univariate analysis but are not independent predictors of CAD or clinical events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093289     DOI: 10.1194/jlr.M600361-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  97 in total

1.  Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.

Authors:  Hang Pong Ng; Ramona L Burris; Shanmugam Nagarajan
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

Review 2.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

Review 3.  Natural IgM antibodies against oxidation-specific epitopes.

Authors:  Christoph J Binder
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 4.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

5.  Atheroprotective vaccination with MHC-II-restricted ApoB peptides induces peritoneal IL-10-producing CD4 T cells.

Authors:  Takayuki Kimura; Kevin Tse; Sara McArdle; Teresa Gerhardt; Jacqueline Miller; Zbigniew Mikulski; John Sidney; Alessandro Sette; Dennis Wolf; Klaus Ley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-01-13       Impact factor: 4.733

Review 6.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

Review 7.  Atherosclerosis and the role of immune cells.

Authors:  Fulya Ilhan; Sevgi Tas Kalkanli
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 8.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 9.  Atherosclerosis: current pathogenesis and therapeutic options.

Authors:  Christian Weber; Heidi Noels
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

Review 10.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.